Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06885671

Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy

Phase II Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy: SHIFT-PB

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
British Columbia Cancer Agency · Academic / Other
Sex
Female
Age
40 Years
Healthy volunteers
Not accepted

Summary

Partial Breast Irradiation (PBI) is a targeted radiation approach commonly administered post-lumpectomy, specifically targeting the tumour bed. This targeted therapy reduces the exposure to other nearby tissues such as lungs, heart, and chest wall. However, traditional PBI treatment involves lengthy multiple fraction courses which presents a burden to patients from rural and remote communities, who must travel long distances to receive high quality cancer care. The purpose of this study is to compare single fraction (SF) PBI vs. multiple fraction (MF) PBI.

Detailed description

Radiation can be delivered in multiple fractions, or doses, and can take up to several weeks or months of treatment depending on the type of cancer. Radiation can also be offered in a single fraction. Both techniques have evidence for use in clinical care. Multiple fraction is offered to reduce the amount of radiation given at a single time that could reduce late toxicities. However, single fraction radiotherapy is more cost-effective and saves patient time. With this trial, we will compare single fraction vs. multiple fraction PBI in regards to their impact on quality of life, rates of provider and participant reported toxicities, and local control.

Conditions

Interventions

TypeNameDescription
RADIATIONMultiple Fraction PBIParticipants randomized to Arm 1 will receive PBI with a dose of 26 Gy in 5 daily fractions.
RADIATIONSingle Fraction PBIParticipants randomized to Arm 2 will receive PBI in a single fraction with a dose of 13 Gy.

Timeline

Start date
2026-01-01
Primary completion
2029-12-31
Completion
2029-12-31
First posted
2025-03-20
Last updated
2025-11-17

Source: ClinicalTrials.gov record NCT06885671. Inclusion in this directory is not an endorsement.